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Radiation oncology is a rapidly evolving specialty. In analogy 
with the evolution from conventional radiotherapy over 3D 
conformal radiotherapy to intensity modulated radiotherapy 
and volumetric modulated arc therapy there has been a shift 
from the use of anatomical imaging (e.g. CT, MR) to 
functional imaging (e.g. DW-MRI, DCE-MRI) and biological 
imaging (e.g. 18F-FDG PET).  In the current process of 
radiation treatment, the radiobiological response of tumor 
and normal tissue in patients is monitored non-invasively by a 
variety of imaging techniques. Integration of these imaging 
techniques into therapy selection strategies and radiation 
treatment can serve several purposes.  
First, pre-treatment assessments can steer decisions on the 
radiation treatment as such or on the combination with other 
modalities.  
Second, biology-based objective functions can be introduced 
into the radiation treatment planning process by co-
registration of molecular imaging. Relevant radiobiological 
parameters that can be assessed include tumour burden, 
tumour hypoxia, tumour proliferation and tumour 
metabolism. This would allow us to generate customized 
heterogeneous dose distributions with escalated doses to 
tumour areas where radiotherapy resistance mechanisms are 
most prevalent. However, there are some hurdles to 
overcome including the discrepancy between resolution of 
imaging techniques and spatial scale at which radiosensitivity 
is determined and the treatment induced temporal and 
spatial changes in tumor morphology and biology.  
Third, monitoring of temporal and spatial variations in these 
radiotherapy resistance mechanisms early during the course 
of treatment can discriminate responders from non-
responders.  With such information available shortly after the 
start of treatment, modifications can be implemented or the 
radiation treatment plan can be adapted based on the 
biological response pattern.  
In this teaching lecture, some background on the different 
imaging techniques at our disposal for early response 
monitoring wil be given and examples of current applications 
and future prospectives for the further integration of imaging 
in the radiation treatment process will be shown.  
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Uncertainties are still a major challenge in cancer treatment. 
The resulting deviations between planned dose and delivered 
dose need to be minimized. 
The widely used PTV-approach contains several pitfalls. 
Firstly, it is based on a single patient-snapshot in time, 
whereas patient treatment is a dynamic process. Secondly, 
expanding the clinical target volume (CTV) to the planning 
target volume (PTV) always entails an increased dose in the 
organs at risk (OARs). Lastly, it is geared towards geometric 
uncertainties in conjunction with conventional radiotherapy 
and fails in hadron-based therapy. 
For more than a decade, alternate approaches have been an 
active area of research. Thus, there is a multitude of 
methods to be found in literature. While their sheer number 
can be overwhelming, the vast majority fits in two distinct 
categories. On one hand, there are methods that strive to 
control the dose to each element in a volume of interest. On 
the other hand are algorithms, that control the outcome 
metric (e.g. max dose, equivalent uniform dose (EUD)). 
Even though they have considerably different prerequisites, 
strength and weaknesses, they share the common goal of 
target dose escalation and/or improved OAR sparing. This 
also and especially includes non-conventional modalities such 
as hadron-based therapy. Fortunately, with the increasing 
availability of imaging information, the wide-range 
deployment of next generation treatment planning via such 
methods is feasible. 
This teaching lecture will elaborate the general differences 
between both schools of thought, as well as present their 
similarities. It turns out that, upon closer inspection, even a 
quantitative relation can be established. The lecture will also 
include an excursion into algorithm-internal uncertainty 
management. More specifically, it will cover effects that 
arise from finite sample sizes, e.g. due to a limited number 
of images available at the time of planning. The impact of 
treatment fractionation on uncertainty handling will also be 
touched upon. It is the ultimate goal of the lecture to build a 
mind map about different kinds of uncertainties, and how 
they may be tackled. This will be underpinned with an 
exemplaric overview of current literature. 
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Medical images of various modalities are important factors in 
establishing diagnosis and stage of the disease, and are used 
extensively before, during and after radiotherapy of cancer 
patients. However, from treatment planning is commenced 
until radiotherapy has ended, image information is except for 
the dose calculation usually considered only in a very strict 
geometrical sense: To define the target and delineate critical 
structures on planning images, and to realign the patient in 
2, 3, 4 or 6 dimensions according to pretreatment imaging. 
Imaging is currently also used in response evaluation after 
radiotherapy. Both tumor progression and normal tissue 
reactions such as radiological pneumonitis are routinely 
evaluated on CT images after radiotherapy for lung cancer. 
Even though a direct link between radiological observations 
and clinical symptoms is not always evident, any radiological 
finding contain information of the tissue response to 
radiation; a response which might be hard to detect clinically 
due to other co-morbidities, and which might contain 
information on potential emerging toxicity.  
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Response evaluation after radiotherapy can be used to make 
population based recommendations, but is untimely to 
influence the delivery of radiotherapy on an individual 
patient basis. There is an active search for associations 
between medical image features obtainable before or early 
during the treatment course and radiological finding, clinical 
symptoms, and tumor control after radiotherapy. Such a 
predictive assay can be related to either normal tissue or 
tumor response on a per patient basis. Ideally the assays 
should include both normal tissue and tumor response since 
intensified treatments typically are related to an increased 
probability of intolerable toxicity. 
A source of medical image information during radiotherapy is 
Cone Beam CT (CBCT). Patient specific density changes of 
normal lung tissue are observable in CBCT images and 
publications on dose response relations during the first part 
of the treatment are available. These observations might 
show a way to a predictive assay of toxicity based on CBCT 
images. Also tumor volume changes are observable during RT 
in CBCT images, and have in a few publications been shown 
to be associated with local control as well as overall survival. 
Pretreatment PET images are another candidate for a 
predictive image assay. Several research groups have 
published associations between PET signals before treatment 
and overall survival. If these results can be confirmed in 
independent studies, PET imaging might be used to select 
patients for escalated radiotherapy. 
A key issue in evaluation of medical images is the image 
quality which has been ever improving. One of the more 
recent improvements has been development of 4D imaging 
which reduced blurring artefacts. 4D images have made it 
possible to evaluate ventilation of specific regions of the 
lungs and it has been suggested that avoidance of irradiation 
of highly ventilated areas of the lung could impact the 
expected toxicity level. Also changes in ventilation during 
radiotherapy might potentially carry information of likely 
level of toxicity. 
Predictive assays based on medical images remains a 
developing field with a potential to generate “free of 
charge” information, since the medical images are already 
available due to their current geometric use. Examples, 
primarily related to lung cancer, of different attempts to 
establish relation between image features and toxicity or 
tumor control will be presented and their potential impact 
addressed. Furthermore, attempts to further improve image 
quality will be commented upon since the image quality 
might be the limiting factor in establishing reliable predictive 
assays based on medical images.    
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Introduction: With the advent of image guided and adaptive 
strategies the management of position variability has become 
commonplace. Nevertheless, margins are still required to 
account for the remaining uncertainties. However, since the 
origin and\or magnitude of these uncertainties is not always 
clear, there is a risk of applying too small margins. The 
purpose of this presentation is to describe the process of 
determining a margin, and to identify all factors involved. 
Margins: The current theory of margin calculation is based on 
group statistics, i.e., the margin is designed in such a way 
that a certain percentage of patients (e.g. 90%) is adequately 
covered. This approach is necessary, as not all patient 
specific errors are known at the time of treatment planning.  
For the actual computation of the margin it is important to 
distinguish systematic and random errors separately, as their 
effect on the margin is quite different. Random errors, 
generally denoted by a standard deviation σ, are different 
every day and cause a blurring of the dose distribution that 
requires a relatively small margin. Systematic errors, 
denoted by a standard deviation Σ, shift the dose distribution 
and require a considerably larger margin. In its most 
simplistic form, assuming a spherical CTV and a large number 
of fractions, the margin to cover 90% of all systematic errors 
with 95% of the prescription dose is approximately 2.5Σ + 
0.7σ. 
Geometrical uncertainties: The major contributing factors 
to the total geometrical uncertainty are delineation, setup 
and organ motion. While the latter two will cause both 
systematic and random errors, delineation uncertainty is a 
purely systematic error source. For setup variation and organ 
motion, both inter- and intra-fractional errors are 
distinguished, with the latter usually being considerably 
smaller than the former. Other errors that can be significant 
are registration inaccuracy, planning system related factors 
(e.g. beam fits) and machine related delivery errors. For 
example, registration inaccuracies will impact the 
delineation uncertainty when using multiple modalities, and 
the accuracy of image guidance. 
Image guidance and residual errors: Most image guidance 
strategies today aim to minimize the random and\or 
systematic geometrical uncertainties by offline or online 
correction protocols based on either surrogates or the actual 
tumor position, and are usually limited to translational 
corrections. Therefore, rotational errors, shape changes, and 
intra-fractional changes are not corrected for. Furthermore, 
once the major contributors to the uncertainty (setup, organ 
motion, delineation) are dealt with, other errors, e.g. 
registration and treatment delivery errors, may become 
significant. Not taking these uncertainties into account when 
designing the margin will result in geometrical misses and 
possible reduced tumor control. On the other hand, the 
commonly used margin formula relies on a number of 
assumptions which may lead to an overestimation of the 
required margin. For example, one of the assumptions is that 
under-dosage to any extent is not tolerated at all, which may 
well be true for a GTV but may be ok to some extent for a 
CTV where there is only a probability of disease. Therefore, 
more complex methods of evaluating adequate dose 
distributions, e.g. probabilistic planning may be required. 
Discussion and conclusions: There are many factors that 
determine the required margin. Delineation uncertainty, 
setup errors, organ and tumor motion are important, but 
once these errors are managed, other smaller errors will 
become significant and ultimately limit how far we can 
reduce our margins. 
  
 
 
 
 
 
 
 
